Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.

However, Vertex announced its second-quarter results following the market close on Thursday. Lo and behold, the company posted a net loss of $3.6 billion, based on generally accepted accounting principles (GAAP). Its non-GAAP loss was $3.3 billion.

Should investors worry about this big loss? Not even for a second.

Continue reading

Source Fool.com